Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Acquisitions (2019)

X4 Pharmaceuticals (XFOR) has disclosed Acquisitions for 1 consecutive years, with $52.8 million as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Acquisitions changed N/A year-over-year to $52.8 million, compared with a TTM value of $52.8 million through Sep 2020, up 300.0%, and an annual FY2019 reading of $26.4 million, changed N/A over the prior year.
  • Acquisitions was $52.8 million for Q4 2019 at X4 Pharmaceuticals, up from -$26.4 million in the prior quarter.
  • Across five years, Acquisitions topped out at $52.8 million in Q4 2019 and bottomed at -$26.4 million in Q1 2019.